Novo Nordisk to present Wegovy and next‑generation obesity data at ECO 2026

Key highlights
  • Novo Nordisk will present 52 abstracts at the European Congress on Obesity (ECO), 12–15 May in Istanbul.
  • Data cover semaglutide (oral 25 mg; injectable 1.7 mg, 2.4 mg, 7.2 mg) and CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) investigational combo.
  • Trials include OASIS 4, ORION, OPTIC, STEP UP, SELECT, REDEFINE and OUTSTEP 1, addressing weight‑loss timelines, body composition, eating control, menopausal symptoms, cardiovascular risk and medication use.
  • Regulatory status: FDA has approved Wegovy injections (1.7, 2.4, 7.2 mg) and the oral 25 mg pill; EMA has approved injections (2.4, 7.2 mg) while the pill is pending review.

Conference overview

Novo Nordisk will present 52 abstracts at the European Congress on Obesity (ECO), 12–15 May in Istanbul, covering clinical trials and real‑world evidence for semaglutide‑based treatments and the investigational CagriSema combination.

Substances and trials

Data span oral semaglutide 25 mg (OASIS 4, ORION, OPTIC), injectable semaglutide (1.7 mg, 2.4 mg, 7.2 mg; STEP UP, SELECT), and CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg; REDEFINE), plus the OUTSTEP 1 real‑world study.

Clinical and real‑world endpoints

Presentations address early responder analyses, time to weight‑loss thresholds and durability, body composition and proximal muscle strength, control of eating, physical function, menopausal symptom associations (including interactions with menopausal hormone therapy), cardiovascular risk metrics including MACE, antimigraine medication use, and patient preferences for obesity medications.

Selected findings to be presented

Highlights include post‑hoc analyses on semaglutide 7.2 mg and oral 25 mg showing speed and durability of weight loss in early responders, STEP UP and REDEFINE dose–response and body‑composition results, and REDEFINE findings on predicted atherosclerotic cardiovascular disease risk reductions.

Regulatory status

FDA has approved Wegovy injections (1.7, 2.4, 7.2 mg) and the oral 25 mg tablet; EMA has approved injections (2.4, 7.2 mg) while the oral pill is pending review.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

16 November 2026
Novo reports early bone-protection signals from amylin and calcitonin receptor agonists

Findings span an ovariectomized-rat model, small human biomarker studies and exploratory analyses from the 68-week REDEFINE 1 trial.

15 November 2026
Novo reports 25.4% mean weight loss among early CagriSema responders

A post hoc analysis of REDEFINE 1 found 67.8% reached at least 5% weight loss by week 8; separate analyses reported improved physical and psychosocial function.

14 November 2026
Novo reports 21% weight loss with lower-dose CagriSema in phase 3 trial

The 68-week REDEFINE 9 study compared two dose levels with placebo in 309 adults with overweight or obesity without diabetes.

20 October 2026
Novo’s CagriSema linked to ~25% weight loss in women in REDEFINE 1 post hoc analyses

Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.

30 September 2026
Novo Nordisk CagriSema lowers food‑cue brain activity, cuts organ fat and shows bone‑marker reassurance

fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.